{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000053","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-09-08T20:02:45+00:00","discovered_at":"2026-09-08T20:04:02.351009+00:00","generated_at":"2026-09-08T20:04:20.023334+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Keros authorizes $5M buyback after $20M Takeda milestone for elritercept; cash runway to 2H 2028","bullets":["Board approved $5 million share repurchase program of KROS common stock, announced September 8, 2026.","Program follows $20 million development milestone from Takeda Pharmaceuticals triggered by first patient dose in ELRiSE MDS trial of elritercept.","Repurchases may occur in open market or other means; timing depends on market price and conditions; may be suspended or discontinued.","Cash and equivalents were $257.6 million as of June 30, 2026; funding runway extended into second half of 2028 after milestone and buyback.","Milestone confirms elritercept MDS development progress under license agreement with Takeda."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000053","json":"https://secwatch.observer/filing/0001664710-26-000053.json","markdown":"https://secwatch.observer/filing/0001664710-26-000053.md","text":"https://secwatch.observer/filing/0001664710-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/0001664710-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/kros-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:04:20.023334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}